0001562180-24-005082.txt : 20240614
0001562180-24-005082.hdr.sgml : 20240614
20240614164133
ACCESSION NUMBER: 0001562180-24-005082
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240613
FILED AS OF DATE: 20240614
DATE AS OF CHANGE: 20240614
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: MUIR GLENN P
CENTRAL INDEX KEY: 0001181190
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38096
FILM NUMBER: 241045505
MAIL ADDRESS:
STREET 1: C/O HOLOGIC, INC.
CITY: BEDFORD
STATE: MA
ZIP: 01730
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: G1 Therapeutics, Inc.
CENTRAL INDEX KEY: 0001560241
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 263648180
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 700 PARK OFFICES DRIVE
STREET 2: SUITE 200
CITY: RESEARCH TRIANGLE PARK
STATE: NC
ZIP: 27709
BUSINESS PHONE: 919-213-9835
MAIL ADDRESS:
STREET 1: 700 PARK OFFICES DRIVE
STREET 2: SUITE 200
CITY: RESEARCH TRIANGLE PARK
STATE: NC
ZIP: 27709
FORMER COMPANY:
FORMER CONFORMED NAME: G-Zero Therapeutics, Inc.
DATE OF NAME CHANGE: 20121012
4
1
primarydocument.xml
PRIMARY DOCUMENT
X0508
4
2024-06-13
false
0001560241
G1 Therapeutics, Inc.
GTHX
0001181190
MUIR GLENN P
700 PARK OFFICES DRIVE, SUITE 200
RESEARCH TRIANGLE PARK
NC
27709
true
false
false
false
false
Common Stock
2024-06-13
4
A
false
10000.00
0.00
A
205358.00
D
Stock Options (Right to Buy)
2.99
2024-06-13
4
A
false
30000.00
0.00
A
2034-06-13
Common Stock
30000.00
30000.00
D
Represents a restricted stock unit ("RSU") award that vests in its entirety twelve months after June 13, 2024, subject to the Reporting Person's continued service as a director. The Reporting Person has elected to defer vesting of these shares pursuant to the G1 Therapeutics, Inc. Deferred Compensation Plan for Non-Employee Directors. The RSUs will vest upon termination of the Reporting Person's service as a Director on the Company's Board.
Each RSU represents a contingent right to receive one share of Issuer common stock.
Represents (i) 185,358 shares of common stock; (ii) 10,000 RSUs from award granted on June 15, 2023; and (iii) 10,000 RSUs from award granted on June 13, 2024.
The shares underlying this option will vest in their entirety twelve months after June 13, 2024, subject to the Reporting Person's continued service as a director.
/s/ Monica Roberts Thomas, attorney-in-fact
2024-06-14